tiprankstipranks
Trending News
More News >
Aveanna Healthcare Holdings (AVAH)
NASDAQ:AVAH
US Market

Aveanna Healthcare Holdings (AVAH) AI Stock Analysis

Compare
102 Followers

Top Page

AV

Aveanna Healthcare Holdings

(NASDAQ:AVAH)

50Neutral
Aveanna Healthcare shows strength in revenue and EBITDA growth, driven by strategic initiatives and acquisitions. However, high leverage, consistent net losses, and valuation concerns weigh down the score. The technical outlook is neutral, and despite some positive momentum, financial stability remains a critical risk.
Positive Factors
Financial Performance
AVAH reported $45.6m of EBITDA on $505m of revenue, which beat consensus estimates by 22.8% and 2.3%, respectively.
Growth Outlook
Aveanna Healthcare is experiencing above-average volume growth in its core PDS segment, enhancing its long-term growth outlook.
Operational Momentum
Improved state reimbursement and Preferred Payer strategy are driving operational momentum for Aveanna Healthcare Holdings.
Negative Factors
Debt Management
Net leverage is ~1.5x lower than it was just one year ago.
Profitability Challenges
2Q24 marks the first quarter since 2Q22 that EBITDA exceeded interest expense.

Aveanna Healthcare Holdings (AVAH) vs. S&P 500 (SPY)

Aveanna Healthcare Holdings Business Overview & Revenue Model

Company DescriptionAveanna Healthcare Holdings (AVAH) is a leading provider of home healthcare services in the United States. The company operates primarily in the pediatric and adult patient care sectors, offering a comprehensive range of services including private duty nursing, home health and hospice care, therapy services, and medical solutions. Aveanna is committed to delivering high-quality, compassionate care tailored to meet the diverse needs of its patients across various stages of life.
How the Company Makes MoneyAveanna Healthcare Holdings generates revenue through its diverse portfolio of home healthcare services. The primary revenue streams include private duty nursing, which provides continuous skilled nursing care to patients in their homes, and home health and hospice services that offer medical and non-medical care to patients with chronic illnesses or those in need of end-of-life care. Additionally, Aveanna earns income through therapy services, including physical, occupational, and speech therapies, and medical solutions that provide specialized equipment and supplies. The company's earnings are bolstered by strategic partnerships with insurance providers, government programs such as Medicare and Medicaid, and other healthcare organizations, ensuring a steady flow of clients and consistent reimbursement for services rendered.

Aveanna Healthcare Holdings Financial Statement Overview

Summary
Aveanna Healthcare Holdings shows revenue growth, but persistent net losses and high leverage pose financial risks. The company has negative equity and significant debt, though cash flow has improved.
Income Statement
45
Neutral
Aveanna Healthcare Holdings has shown some revenue growth, with a notable increase from $1.89 billion in 2023 to $2.02 billion in 2024. The gross profit margin in 2024 is approximately 31.4%, indicating reasonable efficiency in managing production costs. However, the company has struggled with profitability, reflected in consistent net losses over the years, including a net loss of $10.93 million in 2024. The negative EBITDA in 2024 suggests challenges in operational efficiency. Despite revenue growth, margins are under pressure due to high expenses.
Balance Sheet
30
Negative
The balance sheet shows financial instability, with negative stockholders' equity of $122.09 million in 2024, indicating high leverage and potential financial risk. The debt-to-equity ratio is not calculable due to negative equity, but the high total debt of $1.33 billion is concerning. The company has a low equity ratio due to negative equity, suggesting a weak financial position. The debt levels are significantly high compared to assets, which could limit future financing options.
Cash Flow
50
Neutral
Cash flow analysis reveals improvement, with positive operating cash flow of $32.64 million in 2024 and free cash flow of $26.32 million. This is an improvement from previous years, indicating better cash management. However, the free cash flow to net income ratio is impacted by the consistent net losses, resulting in potential sustainability issues. The growth in free cash flow is a positive sign, but financial challenges persist due to underlying profitability issues.
Breakdown
Dec 2024Dec 2023Dec 2022Mar 2022Dec 2020
Income StatementTotal Revenue
2.02B1.90B1.79B1.68B1.50B
Gross Profit
635.54M595.43M553.23M542.40M454.51M
EBIT
139.79M8.07M26.30M95.97M81.95M
EBITDA
187.38M44.35M-517.28M-9.26M22.13M
Net Income Common Stockholders
-10.93M-134.52M-662.03M-117.04M-57.05M
Balance SheetCash, Cash Equivalents and Short-Term Investments
84.29M43.94M19.22M30.49M137.34M
Total Assets
1.66B1.61B1.71B2.33B1.84B
Total Debt
1.33B1.50B1.36B1.30B1.23B
Net Debt
1.24B1.46B1.34B1.27B1.09B
Total Liabilities
1.79B1.74B1.72B1.70B1.58B
Stockholders Equity
-122.09M-127.44M-4.17M637.95M267.17M
Cash FlowFree Cash Flow
26.32M16.56M-60.41M-27.30M101.38M
Operating Cash Flow
32.64M22.67M-48.40M-11.35M116.62M
Investing Cash Flow
-6.32M-8.79M-25.29M-681.83M-193.54M
Financing Cash Flow
14.03M10.85M62.42M586.33M210.94M

Aveanna Healthcare Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.40
Price Trends
50DMA
4.79
Positive
100DMA
4.73
Positive
200DMA
4.92
Positive
Market Momentum
MACD
0.08
Negative
RSI
63.79
Neutral
STOCH
65.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVAH, the sentiment is Positive. The current price of 5.4 is above the 20-day moving average (MA) of 4.67, above the 50-day MA of 4.79, and above the 200-day MA of 4.92, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 63.79 is Neutral, neither overbought nor oversold. The STOCH value of 65.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVAH.

Aveanna Healthcare Holdings Risk Analysis

Aveanna Healthcare Holdings disclosed 56 risk factors in its most recent earnings report. Aveanna Healthcare Holdings reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Aveanna Healthcare Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$1.05B25.718.37%3.71%1.32%
70
Outperform
$931.95M37.9611.28%30.04%43.47%
67
Neutral
$1.09B39.246.72%2.39%14.30%76.89%
AMAMN
54
Neutral
$747.97M18.62-21.08%-18.13%-215.78%
BKBKD
54
Neutral
$1.58B-91.17%3.88%-34.30%
52
Neutral
$5.15B3.56-42.52%2.83%14.56%-0.53%
50
Neutral
$934.50M42.49%9.05%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AVAH
Aveanna Healthcare Holdings
5.40
2.92
117.74%
AMN
AMN Healthcare Services
22.00
-37.01
-62.72%
BKD
Brookdale Senior Living
6.84
-0.15
-2.15%
HCSG
Healthcare Services
14.27
3.01
26.73%
USPH
US Physical Therapy
74.07
-28.79
-27.99%
PNTG
Pennant Group
28.58
5.19
22.19%

Aveanna Healthcare Holdings Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: 12.03%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call reflected strong financial performance with significant revenue and EBITDA growth, successful execution of strategic initiatives, and a promising acquisition. However, challenges in the labor market and seasonal cash flow issues present areas of concern.
Q1-2025 Updates
Positive Updates
Significant Revenue Growth
Revenue for the first quarter was approximately $559 million, representing a 14% increase over the prior year period.
Substantial Increase in Adjusted EBITDA
First quarter adjusted EBITDA was $67.4 million, representing a 93.1% increase over the prior year period, primarily due to the improved pay rate environment and continued cost savings initiatives.
Preferred Payer Strategy Success
Preferred payer agreements increased to 24, accounting for approximately 54% of total PDS MCO volumes, up from 50% in Q4.
Private Duty Services (PDS) Growth
Revenue for the PDS segment was approximately $460 million, a 16.5% increase over the prior year, driven by a 6.1% increase in care volume.
ThriveSkilled Pediatrics Acquisition
The acquisition is expected to enhance Aveanna's preferred payer and government affairs strategies, with the transaction on target to close in the coming weeks.
Negative Updates
Challenging Labor Environment
While there are improvements, the labor environment remains a primary challenge, affecting growth trajectory.
Seasonal Cash Flow Challenges
Cash used by operating activities was $8.6 million, and free cash flow was negative $12.9 million, noting that Q1 typically represents a seasonal low point.
Company Guidance
During the first quarter of 2025, Aveanna Healthcare Holdings Inc. reported a revenue of approximately $559 million, marking a 14% increase over the same period last year. The adjusted EBITDA for the quarter was $67.4 million, reflecting a significant 93.1% rise from the previous year. This growth was largely attributed to an improved pay rate environment and ongoing cost-saving measures. The company's private duty services segment experienced a 16.5% revenue increase, while home health and hospice, as well as medical solutions, saw growths of 3.9% and 3.6%, respectively. Additionally, Aveanna's preferred payer strategy showed progress, with preferred pay agreements accounting for 54% of its total private duty services managed care organization volumes, up from 50% in the previous quarter. Looking ahead, Aveanna projects its 2025 revenue to exceed $2.15 billion and adjusted EBITDA to surpass $207 million.

Aveanna Healthcare Holdings Corporate Events

Executive/Board ChangesShareholder Meetings
Aveanna Healthcare Holds 2025 Annual Stockholders Meeting
Neutral
May 9, 2025

On May 9, 2025, Aveanna Healthcare Holdings Inc. conducted its 2025 Annual Meeting of Stockholders. During the meeting, three Class I directors were elected to the Board for three-year terms, Ernst & Young LLP was ratified as the independent public accounting firm for the fiscal year ending January 3, 2026, and a non-binding advisory resolution on executive compensation was approved. No other matters were addressed at the meeting.

Spark’s Take on AVAH Stock

According to Spark, TipRanks’ AI Analyst, AVAH is a Neutral.

Aveanna Healthcare Holdings is experiencing revenue growth and improved cash flow management, with positive guidance from recent earnings calls. However, persistent financial instability, high leverage, and valuation concerns weigh on the stock’s outlook. The technical analysis shows neutral market sentiment, suggesting a cautious approach is warranted.

To see Spark’s full report on AVAH stock, click here.

Business Operations and StrategyFinancial Disclosures
Aveanna Healthcare Highlights Financial Performance in Presentation
Positive
May 9, 2025

On May 9, 2025, Aveanna Healthcare Holdings Inc. released a financial presentation to investors, emphasizing the company’s use of its website as a primary channel for distributing important information. The presentation highlighted Aveanna’s financial performance and operational statistics, including over $2.15 billion in revenue and a significant presence across 34 states with 26,500 caregivers. The company continues to focus on growth strategies and maintaining a diverse payor mix, which is crucial for its financial stability and market positioning.

Spark’s Take on AVAH Stock

According to Spark, TipRanks’ AI Analyst, AVAH is a Neutral.

Aveanna Healthcare Holdings shows growth in revenue and cash flow but faces significant financial instability due to high leverage and consistent net losses. Technical analysis is neutral, with limited positive momentum. Valuation concerns persist due to a negative P/E ratio. The earnings call and corporate events provide a cautiously optimistic outlook, but substantial challenges remain, impacting the overall stock score.

To see Spark’s full report on AVAH stock, click here.

Business Operations and StrategyFinancial Disclosures
Aveanna Healthcare Reports Strong Q1 2025 Financial Performance
Positive
May 8, 2025

Aveanna Healthcare Holdings reported a strong financial performance for the first quarter of 2025, with a 14.0% increase in revenue to $559.2 million and a significant rise in adjusted EBITDA by 93.1% compared to the previous year. The company also revised its full-year 2025 revenue guidance to exceed $2.15 billion and adjusted EBITDA to surpass $207 million, reflecting positive momentum and strategic transformations, including successful cost reductions and improved reimbursement rates.

Spark’s Take on AVAH Stock

According to Spark, TipRanks’ AI Analyst, AVAH is a Neutral.

Aveanna Healthcare Holdings demonstrates revenue growth and improving cash flow, yet struggles with high leverage and consistent net losses. The technical outlook is neutral, and valuation metrics are concerning. The earnings call highlights strategic initiatives for future growth, but labor market challenges and muted segment growth present risks. Overall, the stock’s performance is hindered by financial instability and valuation concerns.

To see Spark’s full report on AVAH stock, click here.

Executive/Board Changes
Aveanna Healthcare Director Resigns Due to Health Reasons
Neutral
Mar 28, 2025

On March 27, 2025, Dr. Sheldon Retchin, a Class III Director of Aveanna Healthcare Holdings Inc., resigned from the Board of Directors due to personal health reasons. His departure was not related to any disagreements with the company’s operations or policies. Dr. Retchin was an independent director and served on both the Audit Committee and as Chair of the Clinical Quality Committee.

Business Operations and StrategyFinancial Disclosures
Aveanna Healthcare Projects Strong 2025 Financial Outlook
Positive
Mar 14, 2025

On March 14, 2025, Aveanna Healthcare Holdings released a financial presentation to investors, highlighting key operational statistics and financial guidance for 2025. The company projects revenues between $2.10 billion and $2.12 billion, with an adjusted EBITDA of $190 million to $194 million. Aveanna operates 341 locations with 26,500 caregivers, delivering 41.6 million homecare hours. The company emphasizes its strategic use of its website for distributing important information, underscoring its commitment to transparency and timely communication with stakeholders.

Business Operations and StrategyFinancial Disclosures
Aveanna Healthcare Reports Strong Q4 2024 Financial Results
Positive
Mar 13, 2025

Aveanna Healthcare Holdings reported strong financial results for the fourth quarter and full year of 2024, with a notable 8.6% increase in revenue to $519.9 million and a significant rise in adjusted EBITDA by 42.8% compared to the previous year. The company also provided a positive outlook for 2025, expecting revenue between $2.10 and $2.12 billion and adjusted EBITDA between $190 and $194 million, driven by strategic cost reductions and enhanced government and payor partnerships.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.